BNP Paribas Asset Management
CYCN icon

BNP Paribas Asset Management’s Cyclerion Therapeutics CYCN Stock Holding History

BNP Paribas Asset Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,324
Closed -$806K – 832
2019
Q3 		$806K Buy
3,324
+28
+0.8% +$6.05K 0.01% 698
2019
Q2 		$755K Buy
+3,296
New +$933K 0.01% 698

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
AWH Capital Dallas, Texas $110M AUM 44.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BNP Paribas Asset Management's CYCN Position: Q4 2019 in Review

BNP Paribas Asset Management sold out of Cyclerion Therapeutics (CYCN) in Q4 2019, closing a stake of 3,324 shares — an estimated $806K sold.

BNP Paribas Asset Management first reported a position in CYCN in Q2 2019 and held it in 2 quarters. The position peaked at $806K in Q3 2019. 77 funds tracked by Wall St. Rank hold CYCN as of Q4 2019.

  • BNP Paribas Asset Management reported no remaining Cyclerion Therapeutics position as of Q4 2019 after selling out during the quarter.
  • BNP Paribas Asset Management sold 3,324 Cyclerion Therapeutics shares in Q4 2019, an estimated $806K.
  • BNP Paribas Asset Management first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 2 quarters.
  • BNP Paribas Asset Management's Cyclerion Therapeutics position peaked at $806K in Q3 2019.
  • 77 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2019.

Based on BNP Paribas Asset Management's 13F filing for Q4 2019, filed 11 Feb 2020.